Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.
Cohesity adds Sophos scans to backup recovery tools – SecurityBrief Australia
Cohesity adds Sophos scans to backup recovery tools SecurityBrief Australia
